LOGIN 
15 February 2023
GPI provides a way to build your own unique pricing model and forecast the impact of decisions you make using value-based pricing methodology. You can then test different scenarios, compare prices across countries, and weigh up the impact of different launch strategies on the market.
Challenges faced by orphan drug developers
| Analogue Selection for Orphan Asset | When there is no standard of care (SOC) or comparable products. This makes it difficult to do any benchmarking, and typically your competitors in the pipeline are also doing the same forecasting. |
| ROI from Payer Insights | There is difficulty in measuring commercial impact from qualitative payer insights. Conveying what this means commercially and how to communicate this to internal stakeholders. |
| Changing Policies and Payer Landscapes | The current landscape may not be reflective of the anticipated landscape at time of launch. For example, we know that Germany is revisiting how they value orphan products. In 5 years from now, orphan products may not have the same value or premium as they do now. So, the strategy and assessment need to reflect the future. |
| The limitation in being able to weigh up several scenarios | Your product’s price forecast is based on many assumptions that change as the product develops. What if the landscape shift and you need to quickly test a slightly different TPP? How does that affect your position in the market? What if you want to test more than the 2-3 scenarios that you discussed with payers in primary research? |
Orphan assets are often viewed as high risk, having limited data, and not having been historically reimbursed which means that it can be even more difficult to find a value proposition which will attract the right type of payer.
While there is no one-size-fits all solution, and each orphan asset will be unique in its development path, the chances of success can be maximised with the following considerations:
4 Key Considerations to Unlock Value for your Orphan Asset
Consider the future:
Considering payer value perception now versus time of launch may affect potential. As the landscape within an indication may become more competitive, and as the payer landscape changes with more cost containment methods or benefit for innovation understanding the future landscape and how this will impact an orphan asset is really important.
Quantify value:
Quantify value rather than relying on qualitative evidence. By being less reliant on qualitative methods will allow easier assessment of value in a methodical way to help to compare value of an asset particularly within a landscape with limited comparators and potential other pipeline products.
Analogue selection:
Carefully select analogues to help demonstrate value. You can select analogues that are not necessarily within the indication or a similar indication by focussing on specific analogue attributes that will help to demonstrate value.
Early access programmes (EAP):
EAP for access that helps with data collection. Consider markets with early access programmes, particularly in France, to support further data collection and support reimbursement success.
The GPI Platform
Using the latest technology and robust data sources, GPI delivers rapid value assessment and price prediction to inform:
- Portfolio strategy and prioritisation,
- Investment decisions for early assets,
- Strategic price and access planning for assets leading up to launch, and,
- Price revisions throughout the product lifecycle
Within our tool we can predict price forecasting of orphan assets but also for dynamic scenario analysis. 3 common types of scenarios that we often look at include:
- Price type
- Clinical evidence
- Landscape changes
GPI enables quick, data-driven scenario analysis which empowers informed decision-making in early clinical development.
See how GPI combines it proprietary data, methodology and consulting expertise, by viewing our research example, winner of the ISPOR research award.
To learn more about what GPI can do for your orphan asset, reach out to us below.
You can also stay up-to-date with the latest GPI content by signing up to receive news, research and insights direct to your inbox.